1.
Image_1_Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands.jpeg
2.
Image_2_Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands.jpeg
Image_3_Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands.jpeg
Image_4_Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands.jpeg
Flow chart inclusion and exclusion process.
The integrated theoretical framework for factors influencing IPC in disability care settings, informed by various implementation science theories [17, 22–30], adapted to the result...
Flowchart of study participants.
Cost-effectiveness plane reflecting the probability that blended ACT is cost-effective compared to CBT in terms of treatment responders.
Cost-effectiveness plane reflecting the probability that blended ACT is cost-effective compared to CBT in terms of QALYs (cost-utility).
Acceptability curve reflecting the probability that blended ACT is cost-effective compared to CBT in terms of QALYs (cost-utility) at different willingness-to-pay ceilings.